Two brutal recessions wiped out dividends across the market, yet a handful of healthcare companies kept raising their payouts through every quarter of both downturns. Here are the four names that made…
Abbott just scored a regulatory first in diabetes care that no rival has matched, yet the stock sits well below where it traded a year ago. The real question is what it…
Wall Street analysts made bold moves Thursday, slashing targets on some names while dramatically upgrading others, and the gap between winners and losers tells a story about where smart money is quietly…
SCHD charges just 0.06% per year, but taxable investors who lived through the March reconstitution discovered a second bill arriving in a very different form. Here is what the expense ratio line…
Abbott Laboratories has shed billions in market value this year while the broader market climbed, yet one analyst on Wall Street sees a dramatically different story unfolding beneath the surface of the…
JNJ is pruning its portfolio while Abbott just dropped $21 billion to expand into cancer diagnostics, and the two strategies are pulling their stocks in completely opposite directions. Which move looks smarter…
Wall Street still prices Abbott like a slow-and-steady dividend stalwart, but a pair of massive strategic moves beneath the surface suggests that framing may be costing investors a significant opportunity.
Abbott is down nearly 23% this year while Pfizer dangles a 7% yield, and both just beat Q1 estimates. One of these discounts is a genuine buying opportunity and the other is…
Abbott and Danaher both reported Q1 2026 results, but the businesses underneath those numbers point in opposite directions, and choosing the wrong one right now costs more than just a few percentage…
Passive income is characterized by its ability to generate revenue without requiring the earner’s continuous active effort, making it a desirable financial strategy for those seeking to diversify their income streams or…
Pre-Market Stock Futures: Futures are trading lower as we get ready to start the third quarter after a record-setting second quarter that saw the Dow Jones Industrial Average close at 52,317, up…
Abbott Laboratories (NYSE:ABT | ABT Price Prediction) at $90.53 is a Buy. The healthcare giant has been swept up in a sector-wide rotation out of defensive names, even as its diabetes franchise…
Abbott Laboratories (NYSE:ABT | ABT Price Prediction) is a stock with characteristics suited to multi-decade ownership, because its four-segment healthcare engine, 54 consecutive years of dividend increases, and recession-resistant end markets give…
Alex Sirois Pre-Market Stock Futures: Futures are trading higher as we hit the midweek point. All major indices finished lower on Tuesday as the deadline for the ceasefire approached, amid threats to cancel talks…
Boston Scientific (NYSE: BSX | BSX Price Prediction) trades around $61, with analyst price targets ranging from $69 (conservative) to $124 (optimistic), implying substantial upside. Abbott Laboratories (NYSE: ABT) trades near $95…
